June 16 (Reuters) - Drugmaker Supernus Pharmaceuticals

said on Monday it will acquire Sage Therapeutics ( SAGE )

, which makes treatments for neurological conditions, in

a deal worth up to $795 million.

Supernus has offered $8.50 in cash for each of Sage's share

and up to $3.50 per share in cash if certain milestones are

achieved.

Shares of Sage Therapeutics ( SAGE ) were halted in premarket

trading.

(Reporting by Bhanvi Satija and Puyaan Singh in Bengaluru;

Editing by Shinjini Ganguli)